Zim Laboratories Limited
Incorporated in 1989, Zim LaboratoriesLtd manufactures formulation drugs andpre formulation ingredients in India andmarkets and sells these within and outside India
What Zim files
- Others74
- Investor Meet33
- Important19
- Board Meeting13
- Updates9
- JV/Acquisition6
Zim Laboratories reported a solid Q3 FY26, with total operating income up 12.8% YoY to ₹108.7 Cr. EBITDA also grew 9.1% YoY to ₹14.5 Cr, and the company achieved a positive PAT of ₹4.4 Cr, recovering from a previous quarter's loss. For the 9M FY26, revenue remained largely flat at...
Zim Laboratories' H1FY26 operating income dipped to 160.5 Cr (down 7.8% YoY), with EBITDA at 13.5 Cr (down 32.2%), leading to a net loss of 2.3 Cr. This was largely due to a critical EU-GMP audit observation impacting European commercialization. However, Q2FY26 showed a sequential rebound, with operating income up...
**Financial Highlights:** Q1FY26 operating income for Zim Laboratories was ₹71.8 Cr, down 12.3% YoY. EBITDA declined 36.7% to ₹5.7 Cr, with margins at 7.9%. The company reported a net loss of ₹1.9 Cr, impacted by lower revenue and higher costs. Dossier outlicensing fees contributed ₹4.5 Cr. **Strategic Initiatives & Growth...
1. Financial Highlights: ZIM Laboratories reported total operating income of ₹379 Cr, up 3.2% YoY, led by export growth of 8.9% to ₹312.5 Cr, which accounted for 82% of revenue. EBITDA rose 6.4% YoY to ₹49.5 Cr with margins expanding to 13.1%. However, PAT declined to ₹12.2 Cr owing to...